The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Angela DeMichele, MD, MSCE
Alan and Jill Miller Professor in Breast Cancer Excellence, Co-leader, Breast Cancer Research Program, Co-director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Rajarshi Sengupta, PhD
Director, scientific research analysis and communication, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. 
Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Byline
Angela DeMichele, MD, MSCE
Alan and Jill Miller Professor in Breast Cancer Excellence, Co-leader, Breast Cancer Research Program, Co-director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Rajarshi Sengupta, PhD
Director, scientific research analysis and communication, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account